Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma

Anticancer Research

Volumn 21, Issue 1 B, 2001, Pages 711-715

  Hsu, C H ^a   Chen, J ^a   Wu, C Y ^a   Cheng, A L ^a   Pu, Y S ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chemotherapy; Tamoxifen; Transitional cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; METHOTREXATE; TAMOXIFEN; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; PRIORITY JOURNAL; SEPSIS; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UROGENITAL TRACT TUMOR;

AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; REMISSION INDUCTION; SEPSIS; TAMOXIFEN; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 0035062381     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Palliative chemotherapy in advanced bladder cancer
2. Chemotherapy for advanced bladder cancer
3. Chemotherapy for invasive bladder cancer
4. Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study
5. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of urothelium. Efficacy and patterns of response and relapse
6. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
7. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
8. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy
9. Clinical multidrug resistance in cancer: A multifactorial problem
10. Expression of MDR-1 gene in transitional cell carcinoma and its correlation with chemotherapy response
11. Tamoxifen enhances the chemosensitivity of bladder carcinoma cells
12. Mechanism of drug resistance
13. High-dose tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine
14. High-dose (480 mg/day) tamoxifen with etoposide: A study of a potential multidrug resistance modulator
15. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia
16. Toxicity and response criteria of the Eastern Cooperative Oncology Group
17. Nonparametric estimation from incomplete observations
18. Effect of tamoxifen on cell lines displaying the multidrug-resistance phenotype
19. Triphenylethylenes: A new class of protein kinase C inhibitors
20. Inhibition of membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen
21. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer
22. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment
23. Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: A potential use in intravesical chemotherapy
24. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma
25. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma
26. High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma
27. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, darcarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma
28. Unusual clinical presentation of upper urothelial carcinoma in Taiwan